FX-11

FX-11 is a potent, selective, reversible and competitive lactate dehydrogenase A (LDHA) inhibitor, with a Ki of 8 μM. FX-11 reduces ATP levels and induces oxidative stress, ROS production and cell death. FX-11 shows antitumor activity in lymphoma and pancreatic cancer xenografts[1][2][3].

Product Specifications

CAS Number

[213971-34-7]

Product Name Alternative

LDHA Inhibitor FX11

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Apoptosis; Lactate Dehydrogenase; Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/FX-11.html

Purity

99.21

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=C(C1=C2C=C(CC3=CC=CC=C3)C(C)=CC2=C(CCC)C(O)=C1O)O

Molecular Formula

C22H22O4

Molecular Weight

350.41

Precautions

H302, H315, H319

References & Citations

[1]EC Calvaresi. Small molecule inhibitors of lactate dehydrogenase a as an anticancer strategy. 2014.|[2]Le A, et, al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A. 2010 Feb 2;107 (5) :2037-42.|[3]Mohammad GH, et al. Targeting Pyruvate Kinase M2 and Lactate Dehydrogenase A Is an Effective Combination Strategy for the Treatment of Pancreatic Cancer. Cancers (Basel) . 2019 Sep 16;11 (9) :1372.